satisfaction which reached AUC¼0.743 [ 95%CI 0.691 -0.795 ] when added to age, sex, BMI, WOMAC score and poor sleep quality (see Figure 1 ). Conclusions: Our data confirm the strong difference in patient related outcomes for THR and TKR and highlight the importance of understanding the factors that contribute to neuropathic pain like symptoms and to pain in general post TKR.
Purpose: Some prior research findings have suggested that females have poorer outcomes following total knee replacement (TKR) than males. Studies also have suggested that females with the same clinical profile as males are less likely to be offered hip or knee replacement. Moreover, some studies report that females have worse pain and functional status compared to males at the time of TKR. Given that presurgery status remains the strongest predictor of outcome following TKR, this study examined whether females were at risk of poorer pain and functional outcomes at 6 and 12 months following TKR independent of pre-surgery status. Methods:This study utilized data from an existing cohort of 494 people who underwent primary TKR for osteoarthritis. The primary outcomes of interest were the Pain and Function/Daily Activity subscales of the Knee Injury and Osteoarthritis Outcome Score (KOOS) (lower scores indicate worse status) at 6 and 12 months post-surgery. In addition, the patient-completed survey captured age, sex, body mass index (BMI), education level, presence of low back pain (LBP), depression, number of comorbidities, and symptomatic joint count. Descriptive statistics were calculated by sex for the personal and health status characteristics and the KOOS. A sequential series of regression analyses were conducted for each of the pain and function outcomes using the following independent variables: 1) sex; 2) sex and age; 3) sex, age and pre-surgery score of the outcome; and, 4) the latter model plus BMI, education level, low back pain (LBP), depression, number of comorbidities, and symptomatic joint count. P values of 0.05 were considered significant. As change between 6 and 12 months surgery is known to be much less relative to baseline to 6 months, we conducted analyses at 12 months as a validation of the 6 month results. Results: The sample included 323 females and 171 males. Females had worse pain and function scores at baseline compared to males (pain: 39.0 AE 16.5 in females versus 44.9 AE 16.4 in males, p¼0.002; function: 47.7 AE 18.6 in females versus 55.0 AE 17.5 in males, p<0.0001). As well, females had worse pain and function at follow-up (72.2 AE 18.4 vs. 76.1 AE 17.7, p¼0.03; 75.2 AE 17.5 vs 80.5 AE 17.1, p¼0.003, respectively). Females also had worse pre-surgery depression scores (5.6 AE 3.6 vs 4.7 AE 3.2, p¼0.006), higher rates of obesity (BMI >30: 54.2 vs. 36.3%, p¼0.0002), and higher symptomatic joint count (>4: 61.3 vs. 44.4%, p¼0.0004). Initially, regression findings suggested that females had worse outcomes for pain (p¼0.04) and function (p¼0.007) compared to males. However, this effect was lost once baseline pain/functional status were also considered. In the final model, worse outcomes were predicted by pre-surgery pain/functional status, as well as depression, LBP and comorbidity count. The results at 12 months were consistent with those at 6 months. Conclusions: Women appear to have worse outcomes following TKR in part as a function of their greater pain and more limited function presurgery. However, depression and comorbidity, for which women have worse status pre-surgery, further contribute to worse outcomes. These finding suggest that women potentially could achieve comparable outcomes to men if surgery were performed before their symptoms and disability became so severe. This could, in addition, limit the effect of mood or, alternately, interventions to address mood could positively influence outcomes. Purpose: 1. To identify patients who will progress to requiring total joint replacement (TJR) amongst a population with moderate-to severeosteoarthritis (OA) by measuring tissue specific biomarkers in serum thus establishing a panel of prognostic biomarkers that may provide molecular insight into the mechanism and pathology of the progression of OA. 2. Investigate the effect of NSAIDs on the predictive and diagnostic serum profile. Methods: OA patients were randomly selected from clinical trials investigating the anti-NGF therapeutic antibody tanezumab. Serum samples from 240 patients who underwent a TJR (cases) and from 440 control OA patients who did not undergo TJR were used. Control group consisted of w2 patients per case matched on: age (<65 or ! 65 years), Kellgren-Lawrence (K-L) grade, gender, BMI category (<30 or !30 kg/m 2 ), OA severity (severe if both WOMAC Pain and Physical function subscale scores were !7 and the Patient Global Assessment score was !4 (i.e. Poor or Very Poor), otherwise baseline OA severity was classified as not severe). On the average, the OA population was 62 years old, 80% K-L grade !3, females (68%), BMI w31 kg/m 2 , WOMAC pain score of 7. Serum samples were analyzed for bone (Total Osteocalcin, CTX-I, DKK1, SOST), cartilage (C2M, COMP, PIIANP), connective tissue (PINP, ICTP, C1M), synovial tissue (C3M), protease burden (MMP-9) as well as inflammation markers (IL6, hsCRP, VEGF). Classification and Regression Tree analysis was used to identify biomarker phenotypes. Results: For NSAID and non-NSAID users separately, biomarker phenotypes were identified at baseline for patients predisposed for TJR. At baseline, a biomarker combination for patients who used NSAIDs before start of tanezumab clinical trials identified 96% of patients who underwent a TJR and 61% of the patients who did not undergo a TJR. Identification of these biomarker phenotypes lowers the odds of a TJR by 14-fold as compared to not having knowledge of the biomarkers. For patients who did not use NSAIDs, 83% of patients who had a TJR and 63% of the patients who did not undergo a TJR, were identified which lowers the odds of a TJR by 3.6-fold. For patients who used NSAIDs continuously, 84% of patients who had a TJR and 77% of the patients who did not have a TJR, were identified which lowers the odds of a TJR by 4.7-fold. Conclusions: Serological biomarker profiles for predicting TJR were identified irrespective of NSAID use and may assist in identifying those patients whom will need a TJR. The profiles also suggest that NSAID use increases the importance of the role of bone metabolism in TJR pathology. The results need validation on other cohorts, and may finally provide value to patients and payers in selecting the most optimal treatment strategy for moderate-to-severe OA patients. Purpose: The burden of osteoarthritis of the hip and knee is higher in females than in males. Despite this, there remains a gender disparity in the recommendation and uptake of total joint arthroplasty (TJA), with males being more likely to be offered surgery. This may result from a perception that females have a higher rate of complications, including: acute myocardial infarction (AMI), venous thrombo-embolism (VTE), infection, dislocation, early revision, and death. To date, few studies have examined if differences by sex persist in the rates of complications following TJA of the hip (THA) or knee (TKA). Methods: We defined a cohort of patients who received their first primary elective THA or TKA between 2002-2009 utilizing administrative databases from Ontario, Canada. We excluded those who received a primary or revision arthroplasty of the hip or knee prior to April 1, 2002 , those whose first procedure was non-elective (e.g. for cancer, fracture, or injury), or those with a history of hip dysplasia. We compared baseline characteristics and rates of complications following the index TJA for male and female recipients. Cox proportional hazards were used to determine the relationship between sex and the occurrence of specific complications (within 90d: VTE, AMI, mortality; within 2y: dislocation, infection, and revision), defined using validated algorithms, controlling for potential confounders (including income quintile, rurality, and provider volume) and for clustering by surgeons. Results: Between April 1, 2002 and March 31, 2009, there were 97,445 patients who received their first TJA (males: 41,023 -42%; females: 56,422 -58%). Compared with female TJA recipients, males were more likely to have received a THA (43% versus 36%, p<0.001), more likely to come from a rural area (20% versus 15%, p<0.001), and had greater comorbidity (Charlson score of 2þ: 5.5% vs 3.5%, p<0.001). Controlling for these differences, and other potential confounders, male TJA recipients were more likely to experience an infection (adjusted HR 1.41, 95%CI 1.24-1.61, p<0.0001), early revision (adjusted HR 1.24, 95%CI 1.10-1.40, p¼0.0006), or death (adjusted HR 1.26, 95%CI 1.03-1.55, p¼0.03). They were similarly likely to experience all other complications: dislocation (adjusted HR 0.94, 95%CI 0.79-1.12, p¼0.48), AMI (adjusted HR 1.05, 95% CI 0.93-1.19, p¼0.41), and VTE (adjusted HR 0.99, 95%CI 0.88-1.12, p¼0.95). Conclusions: In a population cohort undergoing their first primary TJA, male recipients were at increased risk for early revision, infection and death relative to female recipients. Purpose: Osteophyte formation is one of the hallmarks of osteoarthritis (OA). We have shown that either overexpression of TGF-beta or BMP2 can induce osteophytes in murine knee joints. However, comparing osteophytes induced by experimental OA, TGF-beta or BMP2 showed us that TGF-beta-induced osteophytes rather than BMP2-induced osteophytes more closely resemble those observed in experimental OA. TGF-beta-induced osteophytes develop mainly from
